Copyright © 1992 by the European Society of Cardiology.
© 1992 The European Society of Cardiology
Where now the diuretics in antihypertensive treatment?
University of Munich, Medizinische Poliklinik Munich, Germany
Correspondence: Professor Dr med. Heinnch Holzgreve, University of Munich, Medizinische Poliklinik, Pettenkoferstr. 8a, 8000 Munich 2, Germany
The ultimate aim in treating hypertension is to reduce cardiovascular mortality and morbidity, especially from coronary heart disease and strokes. In several long-term trials this goal has been achieved with antihypertensive therapy in the form of diuretics. Subsequently, diuretics andbetablockers, compared as single agents or with the addition of other agents, did not appear to affect overall cardiovascular morbidity and mortality differentially. Therefore, recommended first-line therapy for hypertension was initially diuretics, followed later by beta blockers as alternatives.
Recently, calcium antagonists and A CE inhibitors have been accepted as equally valuable in the treatment of hypertension because they similarly lower blood pressure, lack any adverse metabolic effects and may be more beneficial than diuretics or beta-blockers on the long-term prognosis of hypertensive patients. Such recommendations are, however, highly speculative and are not supported by trials using cardiovascular mortality and morbidity as endpoints. In order to solve the conflict between proven facts and sound theory, long-term trials comparing older (mainly diuretics) and newer (calcium antagonists, ACE inhibitors, alpha-adrenoceptor blockers) antihypertensive agents are needed. Until such trials are completed, the debate surrounding first-line drugs for antihypertensive treatment will not be resolved.
Key Words: Hypertension • antihypertensive agents • diuretics • cardiovascular mortality and morbidity • serum lipids